A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively (NCT07424404)
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 Years of Age) With Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0054 — Dothan, Alabama
Age range: 5 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (91 Sites)
Showing the first 25 of 91 sites.
- Local Institution - 0054 — Dothan, Alabama
- Local Institution - 0163 — Phoenix, Arizona
- Advanced Research Center Inc. — Anaheim, California
- Local Institution - 0159 — Anaheim, California
- Inland Psychiatric Medical Group. — Chino, California
- Proscience Research Group — Culver City, California
- Local Institution - 0162 — Glendale, California
- Local Institution - 0153 — Los Angeles, California
- Local Institution - 0158 — Orange, California
- Local Institution - 0174 — San Diego, California
- Local Institution - 0089 — San Francisco, California
- Local Institution - 0157 — San Rafael, California
- Local Institution - 0161 — Colorado Springs, Colorado
- Local Institution - 0154 — New Haven, Connecticut
- Local Institution - 0145 — Boca Raton, Florida
- Local Institution - 0160 — Gainesville, Florida
- Local Institution - 0164 — Gainesville, Florida
- Local Institution - 0168 — Hollywood, Florida
- Apg Research, Llc — Orlando, Florida
- Atlanta Center for Medical Research — Atlanta, Georgia
- Salveo Integrative Health - Lawrenceville — Lawrenceville, Georgia
- Denali Health Atlanta, LLC — Stone Mountain, Georgia
- Local Institution - 0175 — Chicago, Illinois
- EmVenio Research Center - Prime Healthcare — Chicago, Illinois
- Boston Children's Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.